suggest that the thiol group in NAC is required for its effects on glial viability and protein quality control.
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Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease are characterized by an imbalance in protein homeostasis, or proteostasis (Angot et al., 2010; Dickson, 2009; Jellinger, 2009; Uversky, 2009; Walker et al., 2006; Xilouri and Stefanis, 2010) . Severe imbalances in proteostasis can elicit proteotoxic stress, inclusion formation, and cell death because of widespread protein misfolding and aggregation. In addition to the accumulation of misfolded proteins in neurodegenerative conditions, the activity of the ubiquitin-proteasome system is lower in postmortem brain tissue from patients with Huntington's, Parkinson's and Alzheimer's disease (Keck et al., 2003; Keller et al., 2000; Lopez Salon et al., 2000; McNaught, 2004; McNaught et al., 2003; Mishto et al., 2006; Seo et al., 2004) . These effects have been modeled in vitro and in vivo with the use of proteasome inhibitors, which lead to the accrual of damaged proteins and cell death through loss of proteostasis (Fornai et al., 2006; Fornai et al., 2003; Le et al., 2014; Li et al., 2012; Pan et al., 2008; Rideout et al., 2005; Rideout et al., 2001; Rideout and Stefanis, 2002; Sawada et al., 2004; Sun et al., 2006; Xie et al., 2010; Zhang et al., 2012; Zhu et al., 2010) .
Most studies of proteotoxicity in the central nervous system (CNS) have examined neurons because this cell type is known to accumulate protein inclusions (Braak and Braak, 1995; Braak et al., 2003) . Furthermore, most therapeutic CNS compounds have been tested with respect to their effects on neurons. However, astrocytes can also contain misfolded or aggregated proteins in neurodegenerative disorders. For example, astrocytes may phagocytose α-synuclein from the extracellular space (Lee et al., 2010) and are known to exhibit α-synuclein + inclusions in Parkinson's disease (Braak et al., 2007; Wakabayashi et al., 2000) . In Alzheimer's disease, astrocytes are hypothesized to phagocytose extracellular β-amyloid (Wyss-Coray et al., 2003) and are immunolabeled by anti-Aβ antibodies (Akiyama et al., 1999; Akiyama et al., 1996; Duyckaerts et al., 2009) . Astrocytes also contain protein deposits in amyotrophic lateral sclerosis (Yang et al., 2003; Yang and Strong, 2012; Yokota et al., 2006) ,
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supranuclear palsy, corticobasal degeneration, and Pick's disease (Komori, 1999) . Furthermore, astrocytes may exhibit higher expression of heat shock proteins in neurodegenerative disorders, another indicator of proteotoxic stress (Dabir et al., 2004; Durrenberger et al., 2009; Kawamoto et al., 2007; Lowe et al., 1992; Renkawek et al., 1994a; Renkawek et al., 1993; Renkawek et al., 1999; Renkawek et al., 1994b; Seidel et al., 2012; Shinohara et al., 1993; Wilhelmus et al., 2006) . These studies confirm that both neurons and glia exhibit loss of proteostasis in neurodegenerative disorders.
The study of proteotoxic stress and chaperone function in astrocytes is important because astrocytes protect neighboring neurons by releasing trophic factors, antioxidants, and metabolic precursors (Allen and Barres, 2009; Kimelberg and Nedergaard, 2010 ). Yet, no currently available therapies target astrocytes for protection from proteotoxicity. Thus, the major goal of the present study was to examine the effects of the glutathione precursor, N-acetyl L-cysteine (NAC), as a protective agent in astrocytes with diminished proteasome function. NAC has been shown to improve some aspects of cognition in patients with Alzheimer's disease (Adair et al., 2001) . Soldiers suffering blast injury in combat experienced a two-fold increase in the resolution of their neurological symptoms when administered NAC within 24 h of the insult (Hoffer et al., 2013) . NAC may also benefit patients with
Parkinson's disease; it appears to cross the blood-brain barrier, raise glutathione levels, and improve motor deficits and dopamine transporter binding in this condition (Holmay et al., 2013; Katz et al., 2015; Martinez-Banaclocha, 2012; Monti et al., 2016; Reyes et al., 2016) . While two previous studies determined that NAC can shield astrocytes from β-amyloid toxicity (Brera et al., 2000; de Ceballos et al., 2001) , it is unknown whether NAC also protects astrocytes against the severe loss of protein quality control associated with proteasome inhibition. To address this gap, we employed the proteasome inhibitor MG132, which has been used to elicit loss of dopaminergic cells and model Parkinson's disease in vivo (Bentea et al., 2017; Lu et al., 2010; Sun et al., 2006; Xie et al., 2010) . Clasto-lactacystin β-lactone and MG132 have been applied in vivo to study the role of the ubiquitin-proteasome system in α-
6 synuclein degradation (Ebrahimi-Fakhari et al., 2011) . Those studies reveal that α-synuclein is degraded by the ubiquitin-proteasome system under both physiological and pathological conditions. Furthermore, a large body of work suggests that pathological α-synuclein blocks the activity of the proteasome particle, suggesting that it might be a trigger that leads to loss of proteasome activity in Parkinson's disease (Chen et al., 2006; Chen et al., 2005; Ebrahimi-Fakhari et al., 2011; Emmanouilidou et al., 2010; Jiang et al., 2007; Lindersson et al., 2004; Petrucelli et al., 2002; Snyder et al., 2003; Stefanis et al., 2001; Zhang et al., 2008) . Collectively, these studies support inhibition of proteasome degradation as a means of modeling neurodegenerative conditions.
We recently showed that NAC protects neuroblastoma cells and primary cortical and hippocampal neurons against proteotoxic or oxidative stress, perhaps by raising the concentration of the antioxidant glutathione (Heinemann et al., 2016; Posimo et al., 2013; Unnithan et al., 2012; Unnithan et al., 2014) . Indeed, most studies of NAC assume that it is effective because it provides a critical precursor, cysteine, for glutathione biosynthesis (Martinez-Banaclocha, 2012; Pocernich and Butterfield, 2012) . However, NAC has also been shown to protect cells through ERK phosphorylation and MAP kinase signaling pathways (Sun et al., 2012; Yan and Greene, 1998; Zhang et al., 2011) .
Furthermore, NAC can reduce disulfide bonds in protein aggregates (Samuni et al., 2013; Sheffner, 1963) . We previously observed that NAC prevented heat shock protein 70 (Hsp70) loss in neuroblastoma cells after treatment with the proteasome inhibitor MG132 (Jiang et al., 2013) . Hsp70 is a key contributor to cellular homeostasis, as it facilitates protein refolding, escorts damaged proteins to the proteasome for degradation, and counters apoptosis (Ciechanover and Kwon, 2017; Fontaine et al., 2016; Kalia et al., 2010; Lanneau et al., 2010; Morimoto, 2008) . Hsc70 is a member of the same chaperone family and, among other functions, guides damaged proteins to the lysosome for chaperone-mediated autophagy (Arias and Cuervo, 2011; Liu et al., 2012; Orenstein and Cuervo, 2010) .
In our previous study on neuroblastoma cells, NAC had no effect on Hsc70 but increased Hsp70
This article has not been copyedited and formatted. The final version may differ from this version. expression, and inhibitors of Hsp70/Hsc70 activity completely abolished the NAC-induced protection (Jiang et al., 2013) . Thus, the second goal of the present study was to test the hypothesis that NAC also protects astrocytes in a heat shock protein-dependent manner. Glutathione synthesis was inhibited with buthionine sulfoximine (Cat. no. 309475000, Acros) (Griffith, 1982) . Buthionine sulfoximine was delivered at a concentration of 25 μM, based on previous reports that this concentration depletes glutathione in astrocytes (Brito et al., 2008; Pizzurro et al., 2014) . Hsp70/Hsc70 activity was inhibited with VER155008 (Cat. no. 3803, Tocris Bioscience, Minneapolis, MN) (Chatterjee et al., 2013; Massey et al., 2010; Saykally et al., 2012) . VER155008
competes for Hsp70 binding (IC50 of 0.5 μM) and has been applied to cells in vitro at concentrations of 10 μM in previous studies (Chatterjee et al., 2013; Massey et al., 2010) . Hsp70/Hsc70 activity was also inhibited by pifithrin-µ or 2-phenylethynesulfonamide (PES, Cat. no. 506155, EMD Millipore), which has previously been administered to cells at concentrations of 10-20 μM Granato et al., 2013; Kondoh and Osada, 2013; Leu et al., 2009; Leu et al., 2011; Schlecht et al., 2013; Sekihara et al., 2013) . Finally, we employed MAL3-101, which has been used to inhibit Hsp70 and increase protein aggregation at concentrations of 10 μM or higher (Adam et al., 2014; Braunstein et al., 2011; Hatic et al., 2012; Huryn et al., 2011; Kilpatrick et al., 2013) . The structure and method of synthesis of MAL3-101 have been published (Fewell et al., 2004) . Concentrations higher than used in the present study were found to be excessively toxic to primary astrocytes. Where indicated, inhibitors were added together with MG132 and NAC. Viability was assessed 48 h after treatment onset, as described below. (Gleixner et al., 2016) .
Cell viability and immunocytochemistry
In addition to counts of Hoechst + nuclei, the DRAQ5 stain for nuclei was also employed in the NMC experiments to assess viability, as described previously . Briefly, DRAQ5 was applied as a 0.5 μM solution (Cat. no. 62251; ThermoFisher Scientific) in 0.3% Triton X-100 for 1 h to fixed cells, followed by 3 washes in 10 mM PBS. DRAQ5 levels were then measured on an Odyssey
Infrared Imager (LI-COR Biosciences, Lincoln, NE).
For immunocytochemistry, fixed cells were washed in PBS, and exposed for 30 min to a fish serum-based blocking solution (Cat. no. 927-40000, Odyssey Block, LI-COR Biosciences) diluted 1:1 in PBS and supplemented with 0.3% Triton X-100. The cells were then incubated overnight at 4 o C in primary antibodies (see Table 1 ) diluted in Odyssey Block/PBS (1:1) with 0.3% Triton X-100 and washed three times with PBS on the following day. Secondary antibodies (see Table 2 ) were diluted in 50%
Odyssey Block in PBS with 0.3% Triton X-100 and applied to cells for 1 hour at room temperature.
Following secondary antibody incubations, cells were washed three times with PBS and immunostaining was captured on an EVOS fluorescent microscope at 200× magnification.
Total and reduced glutathione measures. Total glutathione levels were measured by In-Cell Western analyses and expressed as a fraction of Hoechst-stained nuclei in the same well to control for differences in cell density. This glutathione In-Cell Western assay has been validated in previous studies, in which the signal for glutathione was successfully decreased with buthionine sulfoximine and increased with NAC (Gleixner et al., 2016; Heinemann et al., 2016; Leak et al., 2008; Posimo et al., 2013;  This article has not been copyedited and formatted. The final version may differ from this version. Titler et al., 2013; Unnithan et al., 2012) . Reduced glutathione levels were measured by the luminescent GSH-Glo assay according to the manufacturer's instructions (Cat. no. V6911, Promega, Madison, WI) and as previously described (Gleixner et al., 2016) .
Proteasome activity assay. Cellular lysates were collected 30 minutes after MG132 and NAC treatment, as described (Milan et al., 2015) . Proteasome activity was determined by monitoring the production of 7-amino-4-methylcoumarin (AMC) from Suc-LLVY-AMC (Cat. no. I-1395, Bachem), an established substrate of the chymotrypsin-like activity of the proteasome (Stein et al., 1996) . In brief, 10 µl of each no. 89160-328, VWR). All measurements were performed in duplicate and values were normalized to protein content, as determined by the bicinchoninic acid assay according to the manufacturer's instructions (Cat. no. 23225; ThermoFisher Scientific). The proteasome activity of each sample was calculated by using the following formula:
Immunoblotting. To prepare lysates, cells were harvested 24 or 48 h following treatments and sonicated in cell lysis buffer (recipe from Cell Signaling Technologies, Danvers, MA) supplemented with protease inhibitor cocktail (1:50; Cat. no. P8340, Sigma-Aldrich) and 10 mM sodium fluoride (Leak et al., 2010) .
Equal amounts of protein (as determined by the bicinchoninic acid assay) were separated by gel electrophoresis on 10% polyacrylamide gels and transferred to Immobilon-FL polyvinylidene fluoride
This article has not been copyedited and formatted. The final version may differ from this version. individual replicate wells were averaged to yield an n of 1 for that experiment and this was repeated on at least three occasions for a final n of 3 or more. Statistical significance was determined by two-way or three-way ANOVA followed by the Bonferroni post hoc correction (IBM SPSS Statistics, Version 10.0, Armonk, NY). Differences between groups were only deemed significant when p ≤ 0.05. All data are illustrated as the mean  standard error of the mean.
This article has not been copyedited and formatted. The final version may differ from this version. significantly decreased the toxicity of 0.1 to 0.4 µM MG132 (Fig. 1A & B) . For qualitative assessments of cellular morphology, we employed the astrocyte cytoskeletal markers GFAP and S100β (Fig. 1C) and observed that NAC ameliorated the morphological changes in response to MG132, as expected. These findings suggest that NAC prevents glial cell death in response to proteotoxic stress.
One explanation for the reduction in cell loss by NAC may be that it interferes with the impact of MG132 on proteasome activity, rather than protecting against the downstream consequences of proteasome inhibition. For example, NAC might activate protein factors that protect the proteasome from loss of function (Rodriguez et al., 2014) . Alternatively, NAC has been shown to bind to the proteasome inhibitors lactacystin and bortezomib and directly interfere with their effects on the proteasome particle (Halasi et al., 2013) . To address these possibilities, we examined proteasome activity levels in NAC and MG132-treated samples (Fig.1D ). NAC reduced proteasome activity levels when administered on its own, consistent with previous work (Pajonk et al., 2002 ), but did not exert this effect in the presence of MG132 in our model. Thus, MG132 robustly reduced proteasome activity in the absence or presence of NAC in primary astrocytes, as in our prior studies in neuroblastoma cells (Jiang et al., 2013) . Therefore, NAC does not reduce cell loss simply by interfering with the inhibitory effect of MG132 on the proteasome, but protects astrocytes against the toxic sequelae of MG132-induced loss of protein degradation.
NAC protects astrocytes independent of glutathione synthesis. Previous studies have shown that NAC can increase glutathione levels in MG132-treated cells and primary neurons (Cheng et al., 2016; Heinemann et al., 2016; Posimo et al., 2013) as well as untreated astrocytes (Jurkowska and Wrobel, This article has not been copyedited and formatted. The final version may differ from this version. 2008). Therefore, we assessed glutathione levels in MG132 and NAC-treated astrocytes. MG132 increased intracellular glutathione levels, but NAC attenuated this rise ( Fig. 2A) . To confirm these results, we performed two independent glutathione assays in the absence or presence of buthionine sulfoximine, which inhibits gamma-glutamylcysteine synthetase (also known as glutamate-cysteine ligase), the rate-limiting enzyme in glutathione synthesis (Griffith, 1982) (Fig. 2B-C) . Data obtained with the GSH-Glo assay confirm that MG132 increased the levels of reduced glutathione. Furthermore, NAC raised intracellular levels of reduced glutathione in the absence of MG132 but decreased levels of reduced glutathione in MG132-treated cells (Fig. 2C) . Extracellular reduced glutathione levels were unaffected by NAC or MG132 (Fig. 2D) . While these data were unexpected, they suggest that MG132 elicits compensatory increases in glutathione defenses and that NAC reduces the need for this stress response by blunting MG132 toxicity. In other words, the data support the hypothesis that NAC decreased MG132 toxicity independent of glutathione synthesis. In order to test this hypothesis directly, we treated astrocytes with buthionine sulfoximine to decrease total and reduced glutathione levels inside the cells and measured viability 48 h later (Fig. 2E) . Buthionine sulfoximine exerted no impact on the protection of viability afforded by NAC. These data support the view that NAC protects astrocytes from proteotoxicity in a glutathione-independent manner.
MG132 toxicity is ameliorated in the presence of L-cysteine or D-cysteine. NAC is thought to boost glutathione levels indirectly by increasing the pool of available cysteine (Martinez-Banaclocha, 2016; Zhou et al., 2015) . Naturally occurring L-cysteine can be converted directly into glutathione whereas its unnatural enantiomer, D-cysteine, cannot. Both forms, however, contain a free sulfhydryl group and are protective (Corcoran and Wong, 1986; Huang et al., 1998; Karg et al., 1990; Masukawa et al., 1989; Requejo et al., 2010) . We treated cells with MG132 in the absence or presence of L-cysteine or Dcysteine to test whether these compounds would protect astrocytes equally well against MG132 toxicity, despite exhibiting differences in direct conversion to glutathione (Masukawa et al., 1989) . As
This article has not been copyedited and formatted. The final version may differ from this version. expected, MG132 toxicity was abolished to the same degree in the presence of either L-cysteine or Dcysteine ( Fig. 3A-B) . These findings are consistent with direct protection by free sulfhydryl groups at millimolar concentrations without recourse to glutathione-mediated protection. Given the lack of effect of buthionine sulfoximine on NAC-mediated protection, these results collectively support the view that the protective effects of NAC are glutathione-independent in astrocytes.
In contrast to NAC, L-cysteine, and D-cysteine, N-acetyl-S-methyl-L-cysteine (NMC) lacks a free thiol group. In order to examine whether the thiol functional group is instrumental in eliciting protective effects against MG132, we treated astrocytes with NMC or vehicle in the absence or presence of MG132 (Fig.3C ). As expected, NMC failed to protect against MG132 toxicity. We tested nine concentrations of NMC and performed a second viability assay with the DRAQ5 stain for nuclei to reduce the risk of a Type II error or false negative (Fig.3C-D) . The results of both viability assays were in agreement that the thiollacking molecule NMC failed to confer protection against MG132.
Impact of NAC on heat shock protein levels in astrocytes. In a previous study, we found that Hsp70 levels following proteasome inhibition were higher in NAC-treated cells (Jiang et al., 2013) . However, in astrocytes, NAC attenuated an MG132-dependent rise in Hsp70 (Fig. 4A) . Hsc70 levels were similarly increased by MG132 and NAC also abolished this effect (Fig. 4B) . In our previous study with the N2a neuronal cells, we found that heme oxygenase 1 (HO1, also known as Hsp32) levels exhibited a trend towards an increase in NAC-treated cells after MG132 exposure (Jiang et al., 2013) . Therefore, we also examined HO1 and other heat shock protein levels. As shown in Fig. 4C , MG132 increased HO1 levels in astrocytes and this rise was attenuated by NAC. Hsp25 levels were also raised by MG132, but this effect was not modulated by NAC (Fig. 4D) . However, the phosphorylation of Hsp25 in response to MG132-mediated toxicity was significantly attenuated by NAC (Fig. 4E-F) . Similar to the other heat shock proteins, Hsp40 and Hsp90 were also augmented by MG132 and NAC inhibited this response ( Fig. 4G-H) .
This article has not been copyedited and formatted. The final version may differ from this version. Thus, the patterns we observed were remarkably consistent in that NAC appeared to reduce the need for defensive heat shock protein induction in astrocytes.
The data presented above consistently suggest that heat shock protein levels are reduced by NAC in astrocytes. However, Hsp70 and Hsc70 might still be less damaged and more active in NAC treated cells, and they might work in parallel with NAC to temper proteotoxic stress. To investigate these hypotheses, we inhibited the ATPase activity of Hsp70/Hsc70 with a compound that binds to the chaperone's active site, VER155008 (Chatterjee et al., 2013; Massey et al., 2010; Saykally et al., 2012; Schlecht et al., 2013) . We found that treatment with VER155008 prevented NAC-mediated protection (Fig. 5A) . As in neuroblastoma cells, VER155008 was also significantly toxic and reduced basal viability in astrocytes (Jiang et al., 2013) . Because of the basal toxicity of VER155008, we also expressed astrocyte viability as a percentage of each 0 µM MG132 group, to facilitate rigorous statistical comparisons of the impact of NAC versus vehicle (Fig. 5B) . This alternative illustration of the data clearly reveals that MG132 was equally toxic in the absence or presence of NAC when VER155008 was applied. These findings suggest that astrocytes treated with NAC rely on Hsp70/Hsc70 activity in order to battle proteotoxicity.
All pharmacological inhibitors can exert non-specific effects (Budina-Kolomets et al., 2013).
Therefore, it is advisable to use multiple inhibitors with distinct mechanisms of action, as it would be unlikely that independent classes of inhibitors exert precisely the same off-target effects. Thus, we also treated astrocytes with 2-phenylethynesulfonamide (PES; also known as pifithrin-µ) and MAL3-101, to verify whether Hsp70/Hsc70 activity acts along with NAC to offset proteotoxic stress. PES inhibits the interactions of Hsp70/Hsc70 with several cochaperones and substrate proteins, such as CHIP, BAG-1, and Hsp40 (Granato et al., 2013; Kondoh and Osada, 2013; Leu et al., 2009; Leu et al., 2011) . MAL3-101 specifically interferes with Hsp70/Hsc70 chaperone activity by blocking Hsp40-stimulated ATP hydrolysis (Adam et al., 2014; Braunstein et al., 2011; Fewell et al., 2004; Hatic et al., 2012; Huryn et al., 2011;  This article has not been copyedited and formatted. The final version may differ from this version. Kilpatrick et al., 2013) . Similar to VER155008, PES and MAL3-101 also attenuated the protection afforded by NAC ( Fig. 5C-E) . These findings are consistent with our previous study in N2a cells (Jiang et al., 2013) , and suggest again that NAC protects primary cortical astrocytes through a process that benefits from Hsp70/Hsc70 function. (Fig. 6A) . As expected, NMC failed to exert a similar effect on ubiquitinated proteins (Fig.6B) . Next, we examined the impact of MG132 and NAC on the proteasome regulators PA28α and PA700. If NAC increased the expression of these proteasome subunits, this might also explain why it abolished the rise in ubiquitinated proteins. However, the expression of neither PA28α nor the 42 & 46 kDa subunits of the PA700 particle was altered upon NAC addition ( Fig. 6C-E) .
MG132 triggers a rise in the level
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Discussion
As investigations have shifted away from the traditionally neurocentric view of neurological disorders, it has become increasingly evident that astrocytes are severely impacted in many of these conditions (Charron et al., 2014; Phatnani and Maniatis, 2015) . It is therefore important to identify therapies that protect this cell type in addition to neurons. A few studies have already suggested that NAC can affect astrocytes in experimental models of disease. For example, NAC raises glutathione levels and reduces ischemia-related damage in astrocytes (Gabryel et al., 2005) . NAC also decreases the stressinduced rise in heme oxygenase 1 within astrocytes and reduces lesion volume after traumatic brain injury (Yi and Hazell, 2005) . Furthermore, NAC inhibits the astrocytic increase in nitrite accumulation following inflammatory stimuli such as lipopolysaccharides and cytokines (Pahan et al., 1998) . In studies of pain, NAC elicits analgesia in vivo and this is thought to occur through activation of system xc -within astrocytes (Bernabucci et al., 2012) . NAC also reduces oxidative stress in cultured astrocytes exposed to serum deprivation (Messina et al., 2008) . The present study adds to this body of work by showing for the first time that NAC reduces proteasome inhibitor-induced astrocyte cell death without directly interfering with the ability of MG132 to suppress proteasome activity. These observations suggest that NAC does not merely reduce the efficacy of the toxicant but protects astrocytes against the subsequent loss of protein homeostasis. Consistent with this view, NAC completely abolished the MG132-induced rise in ubiquitinated proteins, suggesting an improvement in protein quality control despite loss of proteasome function. Inhibition of Hsp70/Hsc70 activity, but not of glutathione synthesis, abolished the NAC-mediated protection, suggesting that chaperones are better able to control protein homeostasis in NAC-treated cells.
Proteasome inhibition prevents the degradation of oxidized and misfolded proteins and increases the levels of reactive oxygen species (Dasuri et al., 2011; Ding et al., 2006 previous work has shown that MG132 treatment increases markers of oxidative stress (Alexandrova et al., 2008; Maharjan et al., 2014) . These effects of proteasome inhibitors may have led to the compensatory increase in glutathione that we observed in MG132-treated astrocytes. NAC may prevent oxidative damage directly by increasing the pool of free thiols, indirectly through biochemical incorporation of cysteine into glutathione, or by a yet unidentified mechanism. In the present study, inhibition of glutathione synthesis did not abolish the protection of astrocytes by NAC, supporting the view that not all actions of NAC are mediated through glutathione repletion. Instead, NAC prevented the compensatory increase in glutathione in response to MG132. Similarly, previous reports have demonstrated MG132-induced upregulation of glutathione metabolism genes (Yu et al., 2010) and an alleviation of stress-induced increases in glutathione with NAC application (Tchantchou et al., 2005) .
Accordingly, other investigators have reported that NAC is able to provide protection and scavenge free radicals independent of glutathione synthesis (Aruoma et al., 1989; Han et al., 2010; Steenvoorden and Beijersburgen van Henegouwen, 1998; Wispriyono et al., 1998; Yan et al., 1995) .
System xc -and alanine serine cysteine transporter 1 increase the intracellular pool of L-and Dcysteine (Bridges et al., 2012; Fukasawa et al., 2000) . Cysteines are incorporated into evolutionarily conserved sites on proteins, where they can mitigate oxidative attack (Poole, 2015; Requejo et al., 2010) . NAC, L-cysteine, and D-cysteine contain a free sulfhydryl group, which imparts these molecules with nucleophilic and antioxidant properties and the capacity to form disulfide bonds independent of glutathione (Aruoma et al., 1989; Poole, 2015; Requejo et al., 2010) . In addition to NAC-mediated glioprotective effects, we observed that L-cysteine and D-cysteine robustly protect astrocytes against MG132, perhaps through a glutathione-independent mechanism. D-cysteine can protect against cyanide toxicity and detoxify acetaminophen, but is ineffective at replenishing glutathione stores compared to Lcysteine (Berkeley et al., 2003; Friedman and Levin, 2012; Huang et al., 1998; Masukawa et al., 1989) .
This protective ability is not shared with the disfulfide D-cystine, suggesting that the sulfhydryl group of D-cysteine might mediate detoxification. NMC lacks a thiol group and failed to protect astrocytes against MG132 toxicity or to mitigate the increase in ubiquitinated proteins. Hsp70 contains a reactive cysteine group (Cys306) that is oxidized by redox-active compounds such as methylene blue, and this oxidation inhibits Hsp70 ATPase activity (Miyata et al., 2012) . In addition, the endoplasmic reticulum Hsp70 protein, BiP, has a cysteine group that is oxidized to form a sulfenic acid moiety, also resulting in loss of ATPase activity (Wang et al., 2014) . As proteasome inhibition is known to raise oxidative stress levels, Hsp70 and Hsc70 may not function well under these conditions (Adachi et al., 2009) . Thus, future studies are warranted to determine whether NAC can prevent MG132-induced oxidation of Hsp70 and preserve its ATPase function, which would be consistent with the ablation of its protective abilities with all three Hsp70 inhibitors.
NAC has been shown to protect primary neurons and neuroblastoma cells against proteasome inhibition (Heinemann et al., 2016; Jiang et al., 2013; Li et al., 2012; Posimo et al., 2013) . In contrast to our previous studies on neuroblastoma cells (Jiang et al., 2013) , NAC did not preserve Hsp70 protein levels in primary astrocytes. Previous studies have examined the impact of NAC on Hsp70, and most are in agreement that cellular stress leads to an increase in Hsp70 and that this is reversed by NAC, similar to what we observed in the astrocyte model (Bianchi et al., 2014; Chen et al., 1990; Grogan et al., 2014; Grogan et al., 2013; Hensen et al., 2013; Hou et al., 2013) . Furthermore, some studies have shown that inhibition of Hsp70 activity by PES results in a compensatory increase in Hsp70 protein levels and this response is also attenuated by NAC (Zeng et al., 2014) . Thus, stressed astrocytes may need less Hsp70 in the presence of NAC because it reduces those stimuli that induce Hsp70, including cysteine oxidation and protein denaturation. Consistent with this view, we observed a decrease in ubiquitinated proteins in response to NAC, suggesting a reduction in protein denaturation. However, as argued above, Hsp70 molecules may function better in a less oxidative environment in the presence of NAC, which would reduce the levels of ubiquitinated proteins, protect against cell death, and diminish the need for Hsp70
This article has not been copyedited and formatted. The final version may differ from this version. protein induction. Thus, NAC might work in parallel with Hsp70 chaperone activity, such that only the combination of both is sufficient to elicit a robust protection against MG132 in our model.
One caveat of the present study is that we were not able to measure Hsp70 and Hsc70 activity in cellular lysates, as the ATPase activity of these proteins would be masked by the presence of many other
ATPases. Another important limitation is that pharmacological inhibitors often exert nonspecific effects.
Although some studies have suggested that these inhibitors work on molecules other than Hsp70/Hsc70, some of the effects previously deemed nonspecific may actually be through Hsp70/Hsc70 inhibition. For example, both PES and VER155008 inhibit autophagy (Budina-Kolomets et al., 2013; Leu et al., 2009) , but this might be mediated by loss of Hsc70 activity, as Hsc70 helps escort proteins with a KFERQ motif to the lysosome for degradation by chaperone-mediated autophagy (Arias and Cuervo, 2011; Shin et al., 2005) . Furthermore, both PES and VER155008 reduce the levels of Hsp90 client proteins, also perhaps by inhibiting Hsp70 chaperone action (Budina-Kolomets et al., 2013; Leu et al., 2011; Massey et al., 2010) . PES is thought to prevent p53 accumulation at the mitochondrion, thereby suppressing apoptosis (Leu and George, 2007; Strom et al., 2006) . However, this effect could not explain the present findings because PES increased cell death in our model. In all of our experiments, we employed relatively low concentrations of the inhibitors, which reduces the risk of off-target effects. The use of low concentrations can be of concern if no inhibitory effect is observed, increasing the risk of a Type II error or false negative result. However, all the inhibitors were effective in our study, including buthionine sulfoximine, which lowered glutathione levels as expected.
To further address the concern about nonspecific effects, we used three structurally and mechanistically diverse inhibitors of Hsp70/Hsc70. Given their distinct mechanisms of action, it would be highly unlikely that all inhibitors have the same effects on NAC-mediated protection through coincident off-target effects. It is more likely that they exert similar effects on NAC-mediated protection through
This article has not been copyedited and formatted. The final version may differ from this version. As mentioned above, the present study confirms and extends previous work showing that NAC is protective in experimental models of disease (for some examples, see Clark et al., 2010; Farr et al., 2003; Pocernich et al., 2000; Tucker et al., 2006) . The present study extends the protective effects of NAC to astrocytes under conditions of severe proteotoxic stress and demonstrates that NAC may exert effects other than as a glutathione precursor. Currently there are no safe ways of boosting heat shock protein function in patients with neurodegeneration, but NAC may fulfill this important role.
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